Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548238 | 0.84 | GABRA2 (0.49) | GABRA2GABRB2NPC1RAB9AALDH1A1 | |
| SCHEMBL549092 | 0.82 | GABRA2 (0.53) | GABRA2GABRB2HTTHPGDNPC1 | |
| SCHEMBL548243 | 0.82 | GABRA2 (0.47) | GABRA2GABRB2HPGDNPC1RAB9A | |
| SCHEMBL549131 | 0.79 | GABRA2 (0.45) | GABRA2GABRB2NPC1RAB9AKDM4E | |
| SCHEMBL549105 | 0.79 | POLB (0.54) | GABRA2GABRB2LMNANPC1RAB9A | |
| SCHEMBL548989 | 0.74 | KDM4E (0.43) | GABRA2GABRB2LMNAHPGDNPC1 | |
| SCHEMBL6408072 | 0.72 | NOTUM (0.65) | NOTUMNPBWR1LMNAHTTHPGD | |
| SCHEMBL549116 | 0.70 | POLB (0.54) | GABRA2GABRB2RAB9AKDM4EALDH1A1 | |
| SCHEMBL549152 | 0.69 | GABRA2 (0.58) | GABRA2GABRB2NPC1RAB9AMAPT | |
| SCHEMBL1550424 | 0.68 | RAB9A (0.53) | LMNANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110588-B2 | 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-02-07 | — | — | US | claimed |
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2010-09-02 | — | — | US | claimed |
| US-8110588-B2 | 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-02-07 | — | — | US | disclosed |
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA3, CHRNB3, CHRNA5 | NOTUM 1402/4885NPBWR1 502/4885GABRA2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.